GREENWOOD VILLAGE, Colo., May 21, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the company is scheduled to present a corporate update at the Jefferies Global Healthcare Conference in New York City.
Dr. Vaughan Clift, MD, Ampio's Chief Regulatory and Medical Affairs Officer, and Josh Disbrow, Ampio's Chief Operating Officer and Chief Executive Officer of Ampio subsidiary Luoxis Diagnostics, will provide an update on the company's activities on June 3 rd at 8:30 AM Eastern Time. The presentation will be conducted in Room 1 at the Grand Hyatt New York.
Following the conference the presentation may be accessed through the Ampio website, www.ampiopharma.com, on the "Presentations and Media" page.
About Ampio PharmaceuticalsAmpio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.Forward Looking Statements Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to the completion, timing and size of the registered direct offering, as well as risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: April RamirezOperations CoordinatorAmpio Pharmaceuticals, Inc.Direct: (720) 437-6500Email: email@example.com Logo - http://photos.prnewswire.com/prnh/20120516/MM09116LOGO SOURCE Ampio Pharmaceuticals, Inc.